Pfizer’s Phase 3 Trial Shows Positive Survival in DLBCL
Pfizer Inc. has announced promising Phase 3 study results for ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and rituximab...
Jon Napitupulu
Merck Successfully Acquires Harpoon Therapeutics, Inc.
Merck has successfully completed the acquisition of Harpoon Therapeutics, Inc., making Harpoon a wholly-owned subsidiary of Merck. As a...
Viiv Healthcare Presents Promising Cabenuva Data at CROI
ViiV Healthcare has announced promising interim data from the LATITUDE phase III trial, presented at the CROI 2024. The...
Gilead & Merck’s Phase 2 Data Show Promise for Oral Weekly HIV Regimen
Gilead Sciences and Merck (MSD outside the U.S. and Canada) have shared promising Phase 2 clinical study results for...
Gilead & Merus Team Up for Groundbreaking T-Cell Engagers
Gilead Sciences, Inc. and Merus N.V. have entered into a research collaboration to develop novel dual tumor-associated antigen (TAA)...
EU Validates Datopotamab Apps for Lung & Breast Cancer
The European Medicines Agency (EMA) has validated two marketing authorization applications (MAAs) for Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan,...
Real-World Data Back Veklury for Hospitalized COVID-19 Patients
Gilead Sciences revealed new data from three retrospective studies that suggest its antiviral drug Veklury (remdesivir) not only reduces...
Gilead’s HIV Pipeline Targets Needs & Advances Public Health
Gilead Sciences has revealed a range of positive data from its HIV research pipeline, showcasing its innovative treatment strategies....
AbbVie, OSE Partner for Novel Anti-Inflammatory Antibody
AbbVie Inc. and OSE Immunotherapeutics SA have announced a strategic partnership to develop OSE-230, a monoclonal antibody in the...
SCRI & AstraZeneca Forge Alliance for Cancer Research Tech
Sarah Cannon Research Institute (SCRI), a global leader in conducting community-based clinical trials, has announced a collaboration with AstraZeneca...